Antiphospholipid antibodies mediate autoimmunity against dying cells

References

• Miyakis S., Lockshin M. D., Atsumi T., . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006; 4:295–306.
   PubMed Web of Science ®Google Scholar
• Meroni P. L., Borghi M. O., Raschi E., Tedesco F.. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 2011; 7:330–339.
   PubMed Web of Science ®Google Scholar
• Giannakopoulos B., Mirarabshahi P., Krilis S. A.. New insights into the biology and pathobiology of beta2-glycoprotein I. Curr. Rheumatol. Rep. 2011; 13:90–95.
   PubMed Web of Science ®Google Scholar
• Agar C., van Os G. M., Mörgelin M., . Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010; 116:1336–1343.
   PubMed Web of Science ®Google Scholar
• Agar C., de Groot P. G., Mörgelin M., . β-glycoprotein I: a novel component of innate immunity. Blood. 2011; 117:6939–6947.
   PubMed Web of Science ®Google Scholar
• Price B. E., Rauch J., Shia M. A., . Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J. Immunol. 1996; 157:2201–2208.
   PubMed Web of Science ®Google Scholar
• Maiti S. N., Balasubramanian K., Ramoth J. A., Schroit A. J.. Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members. J. Biol. Chem. 2008; 283:3761–3766.
   PubMed Web of Science ®Google Scholar
• Rauch J., Dieudé M., Subang R., Levine J. S.. The dual role of innate immunity in the antiphospholipid syndrome. Lupus. 2010; 19:347–353.
   PubMed Web of Science ®Google Scholar
• Levine J. S., Koh J. S., Subang R., Rauch J.. Apoptotic cells as immunogen and antigen in the antiphospholipid syndrome. Exp. Mol. Pathol. 1999; 66:82–98.
   PubMed Web of Science ®Google Scholar
• Bondanza A., Rovere-Querini P., Zimmermann V. S., . Requirement for dendritic cells in the establishment of anti-phospholipid antibodies. Autoimmunity. 2007; 40:302–306.
   PubMed Web of Science ®Google Scholar
• Bondanza A., Zimmermann V. S., Dell'Antonio G., . Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis Rheum. 2004; 50:1549–1560.
   PubMed Web of Science ®Google Scholar
• Kuwana M., Matsuura E., Kobayashi K., . Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood. 2005; 105:1552–1557.
   PubMed Web of Science ®Google Scholar
• Tolomeo T., Rico De Souza A., Roter E., . T cells demonstrate a Th1-biased response to native beta2-glycoprotein I in a murine model of anti-phospholipid antibody induction. Autoimmunity. 2009; 42:292–295.
   PubMed Web of Science ®Google Scholar
• Manfredi A. A., Rovere P., Galati G., . Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum. 1998; 41:205–214.
   PubMed Web of Science ®Google Scholar
• Manfredi A. A., Rover P., Heltai S., . Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum. 1998; 41:215–223.
   PubMed Web of Science ®Google Scholar
• Rovere P., Manfredi A. A., Vallinoto C., . Dendritic cells preferentially internalize apoptotic cells opsonized by anti-beta2-glycoprotein I antibodies. J. Autoimmun. 1998; 11:403–411.
   PubMed Web of Science ®Google Scholar
• Rovere P., Sabbadini M. G., Vallinoto C., . Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory context: role of opsonizing anti-beta2-glycoprotein I antibodies. Arthritis Rheum. 1999; 42:1412–1420.
   PubMed Web of Science ®Google Scholar
• Michlewska S., McColl A., Rossi A. G., Megson I. L., Dransfield I.. Clearance of dying cells and autoimmunity. Autoimmunity. 2007; 40:267–273.
   PubMed Web of Science ®Google Scholar
• Patel V. A., Longacre-Antoni A., Cvetanovic M., . The affirmative response of the innate immune system to apoptotic cells. Autoimmunity. 2007; 40:274–280.
   PubMed Web of Science ®Google Scholar
• Sarmiento L. F., Muñoz L. E., Chirinos P., Bianco N. E., Zabaleta-Lanz M. E.. Opsonization by anti-dsDNA antibodies of apoptotic cells in systemic lupus erythematosus. Autoimmunity. 2007; 40:337–339.
   PubMed Web of Science ®Google Scholar
• Kajiwara T., Yasuda T., Matsuura E.. Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: Implications on the development of antiphospholipid syndrome. J. Autoimmun. 2007; 29:164–173.
   PubMed Web of Science ®Google Scholar
• Matsuura E., Hughes G. R. V., Khamashta M. A.. Oxidation of LDL and its clinical implication. Autoimmun. Rev. 2008; 7:558–566.
   PubMed Web of Science ®Google Scholar
• Fürnrohr B. G., Groer G. J., Sehnert B., Herrmann M., Voll R. E.. Interaction of histones with phospholipids–implications for the exposure of histones on apoptotic cells. Autoimmunity. 2007; 40:322–326.
   PubMed Web of Science ®Google Scholar
• Reed J. H., Giannakopoulos B., Jackson M. W., Krilis S. A., Gordon T. P.. Ro 60 functions as a receptor for beta(2)-glycoprotein I on apoptotic cells. Arthritis Rheum. 2009; 60:860–869.
   PubMed Web of Science ®Google Scholar
• Arbuckle M. R., McClain M. T., Rubertone M. V., . Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 2003; 349:1526–1533.
   PubMed Web of Science ®Google Scholar
• Levine J. S., Subang R., Nasr S. H., . Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J. Immunol. 2006; 177:6504–6516.
   PubMed Web of Science ®Google Scholar
• Andreoli L., Pregnolato F., Burlingame R. W., . Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?. J. Autoimmun. 2008; 30:51–57.
   PubMed Web of Science ®Google Scholar
• Tincani A., Andreoli L., Chighizola C., Meroni P. L.. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity. 2009; 42:257–259.
   PubMed Web of Science ®Google Scholar
• Heyder P., Bekeredjian-Ding I., Parcina M., . Purified apoptotic bodies stimulate plasmacytoid dendritic cells to produce IFN-alpha. Autoimmunity. 2007; 40:331–332.
   PubMed Web of Science ®Google Scholar
• Sozzani S., Bosisio D., Scarsi M., Tincani A.. Type I interferons in systemic autoimmunity. Autoimmunity. 2010; 43:196–203.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y., Meroni P. L., Toubi E.. Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?. Curr. Opin. Rheumatol. 2009; 21:495–500.
   PubMed Web of Science ®Google Scholar
• Yin H., Borghi M. O., Delgado-Vega A. M., . Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum. 2009; 60:2468–2471.
   PubMed Web of Science ®Google Scholar
• Fredi M., Tincani A., Yin H., . IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. Arthritis Rheum. 2010; 62:1201–1202.
   PubMed Web of Science ®Google Scholar
• Sebastiani G., Minisola G., Galeazzi M.. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun. Rev. 2003; 2:387–394.
   PubMed Web of Science ®Google Scholar
• Chamorro A. J., Marcos M., Mirón-Canelo J. A., Cervera R., Espinosa G.. Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: Systematic review and meta-analysis. Autoimmun. Rev. 2012; 11:705–712.
   PubMed Web of Science ®Google Scholar
• Lockshin M. D., Salmon J. E.. Are posttranslational modifications of β2-glycoprotein I markers for thrombotic risk? Are they triggers of autoimmunity?. Arthritis Rheum. 2011; 63:2558–2560.
   PubMed Web of Science ®Google Scholar
• Ioannou Y., Zhang J. Y., Qi M., . Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. Arthritis Rheum. 2011; 63:2774–2782.
   PubMed Web of Science ®Google Scholar
• de Laat B., Pengo V., Pabinger I., . The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J. Thromb. Haemost. 2009; 7:1767–1773.
   PubMed Web of Science ®Google Scholar
• Andreoli L., Nalli C., Motta M., . Anti-β-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile?. Ann. Rheum. Dis. 2011; 70:380–383.
   PubMed Web of Science ®Google Scholar
• de Laat B., van Berkel M., Urbanus R. T., . Immune responses against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 2011; 63:3960–3968.
   PubMed Web of Science ®Google Scholar
• Agostinis C., Biffi S., Garrovo C., . In vivo distribution of beta2 glycoprotein I under various pathophysiologic conditions. Blood. 2012; 118:4231–4238 2011.
   Web of Science ®Google Scholar
• Böhm S., Schwab I., Lux A., Nimmerjahn F.. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin. Immunopathol. 2012; 34:443–453.
   PubMed Web of Science ®Google Scholar